Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Sanofi (SNY - Analyst Report) recently announced that it has entered into a research collaboration agreement with the Global Alliance for Tuberculosis (TB) Drug Development (TB Alliance).

Sanofi and TB Alliance will work together to speed up the development of several of Sanofi’s novel TB compounds. Sanofi is developing a vaccine for TB, which is currently in phase I.

We note that several big pharma players including Novartis (NVS - Snapshot Report), Janssen Pharmaceuticals of Johnson & Johnson (JNJ - Analyst Report), GlaxoSmithKline (GSK - Analyst Report), Bayer Healthcare AG (BAYRY - Analyst Report) and AstraZeneca (AZN - Analyst Report) have inked pacts with TB Alliance.

Currently, TB Alliance has more than 20 development programs underway, of which 3 candidates are in late stage development.

We remind investors that earlier this month the US Food and Drug Administration (FDA) granted priority review status to the new drug application (NDA) of Janssen’s TB candidate, bedaquiline (TMC207).

Janssen is looking to get bedaquiline approved as part of a combination therapy for pulmonary, multi-drug resistant tuberculosis (MDR-TB) in adults. FDA approval would make bedaquiline the first TB candidate to gain approval in more than 40 years. Moreover, bedaquiline would be the first and only treatment to be approved for MDR-TB.

According to the World Health Organization, TB affected approximately 8.8 million people in 2010, of which 1.4 million died.

Our Recommendation

We are pleased with the company’s efforts to develop its pipeline. We expect Sanofi to continue to contain operating costs in order to increase earnings in the face of weakening sales of some of its biggest products. We also expect the company to pursue bolt-on acquisitions.

We currently have a Neutral recommendation on Sanofi. The stock carries a Zacks #3 Rank (Hold rating) in the short run.

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
GENERAL FINA GFN 8.20 +5.67%
QIHOO 360 TE QIHU 91.57 +4.38%
VIPSHOP HOLD VIPS 140.01 +3.49%
INVESTMENT T ITG 19.16 +3.34%
VERTEX ENERG VTNR 7.38 +3.07%